Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). Zusätzlich bieten wir Ihnen FANCM Antikörper (82) und und viele weitere Produktgruppen zu diesem Protein an.
Showing 2 out of 2 products:
This case-control study included 2047 BRCA1 and BRCA2 (zeige BRCA2 ELISA Kits)-negative familial breast cancer cases and 2187 controls and revealed an association of FANCM mutations with breast cancer. More pronounced associations were identified for early-onset (before age 51 years) breast cancer and triple-negative breast cancer.
FANCM c.5101C > T nonsense mutation carriers have a reduced breast cancer survival but postoperative radiotherapy may diminish this survival disadvantage.
we provide evidence for the first time showing that the common p.Arg1931* loss-of-function variant in FANCM is a risk factor for familial breast cancer.
FANCM c.5101C>T mutation was not identified in Pakistani triple-negative breast cancer patients
MHF facilitates the processing of multiple types of branched DNAs by the DNA translocase FANCM. MHF complex recognizes branched DNA and stimulates FANCM activity at such a structure to promote genome maintenance.
FANCM is a breast cancer susceptibility gene, mutations in which confer a particularly strong predisposition for triple-negative breast cancer
The MHF complex, which is a heterotetramer that comprises two MHF1 (zeige APITD1 ELISA Kits)-MHF2 heterodimers, is remodeled by FANCM to favor recognition of branched DNA over dsDNA.
The FANCM translocase domain lies in proximity to C-terminal domain and binding fork DNA structures stimulate its ATPase (zeige DNAH8 ELISA Kits) activity.
The traverse frequency was strongly reduced by inactivation of the translocase and DNA binding activities of the FANCM/MHF complex.
Variations of several key residues and the electrostatic property at the active-site region render a catalytically inactive nuclease (zeige DCLRE1C ELISA Kits) domain of FANCM, accounting for the lack of nuclease (zeige DCLRE1C ELISA Kits) activity.
Fancm(Delta2/Delta2) mice also showed unique features atypical for Fanconi anemia (zeige PALB2 ELISA Kits) mice, including underrepresentation of female Fancm(Delta2/Delta2) mice and decreased overall and tumor-free survival.
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity\; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group M.
Fanconi anemia complementation group M
, fanconi anemia complementation group M
, ATP-dependent RNA helicase FANCM
, Fanconi anemia group M protein
, fanconi anemia-associated polypeptide of 250 kDa
, protein Hef ortholog
, Fanconi anemia group M protein homolog